{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:40:49Z","timestamp":1792734049654,"version":"4.5.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Point mutations were found in the adenosine triphosphate (ATP) binding region of BCR\/ABL in 12 of 18 patients with chronic myeloid leukemia (CML) or Ph-positive acute lymphoblastic leukemia (Ph+ ALL) and imatinib resistance (defined as loss of established hematologic response), but they were found in only 1 of 10 patients with CML with imatinib refractoriness (failure to achieve cytogenetic response). In 10 of 10 patients for whom samples were available, the mutation was not detected before the initiation of imatinib therapy. Three mutations (T315I, Y253H, and F317L present in 3, 1, and 1 patients, respectively) have a predicted role in abrogating imatinib binding to BCR\/ABL, whereas 3 other mutations (E255K, G250E, and M351T, present in 4, 2, and 2 patients, respectively) do not. Thus we confirm a high frequency of mutations clustered within the ATP-binding region of BCR\/ABL in resistant patients. Screening may allow intervention before relapse by identifying emerging mutations with defined impacts on imatinib binding. Certain mutations may respond to higher doses of imatinib, whereas other mutations may mandate switching to another therapeutic strategy.<\/jats:p>","DOI":"10.1182\/blood.v99.9.3472","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:33:52Z","timestamp":1034361232000},"page":"3472-3475","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":525,"title":["High frequency of point mutations clustered within the adenosine triphosphate\u2013binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance"],"prefix":"10.1182","volume":"99","author":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zbigniew","family":"Rudzki","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Walsh","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Arthur","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Taylor","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Herrmann","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Lynch","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"From the Institute of Medical and Veterinary Science, Adelaide; Royal Melbourne Hospital; Royal North Shore Hospital, Sydney; Mater Hospital, Brisbane; Royal Perth Hospital; and Novartis Pharmaceuticals Australia, Sydney, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300141381000_B1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med."},{"key":"2020021300141381000_B2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021300141381000_B3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"key":"2020021300141381000_B4","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res."},{"key":"2020021300141381000_B5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med."},{"key":"2020021300141381000_B6","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.","volume":"95","author":"le Coutre","year":"2000","journal-title":"Blood."},{"key":"2020021300141381000_B7","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines.","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood."},{"key":"2020021300141381000_B8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1054\/drup.2001.0180","article-title":"Mechanisms of resistance imatinib (STI571) preclinical models and in leukemia patients.","volume":"4","author":"Weisberg","year":"2001","journal-title":"Drug Resist Update."},{"key":"2020021300141381000_B9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.","volume":"96","author":"Mahan","year":"2000","journal-title":"Blood."},{"key":"2020021300141381000_B10","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."},{"key":"2020021300141381000_B11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021300141381000_B12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1046\/j.1365-2141.2000.02042.x","article-title":"A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia.","volume":"109","author":"Branford","year":"2000","journal-title":"Br J Haematol."},{"key":"2020021300141381000_B13","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase.","volume":"289","author":"Schindler","year":"2000","journal-title":"Science."},{"key":"2020021300141381000_B14","doi-asserted-by":"crossref","first-page":"19585","DOI":"10.1074\/jbc.271.32.19585","article-title":"An activating mutation in the ATP binding site of the ABL kinase domain.","volume":"271","author":"Allen","year":"1996","journal-title":"J Biol Chem."},{"key":"2020021300141381000_B15","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain autophosphorylation at two distinct regulatory tyrosines.","volume":"275","author":"Brasher","year":"2000","journal-title":"J Biol Chem."},{"key":"2020021300141381000_B16","first-page":"470","article-title":"A point mutation in the ABL catalytic domain induces resistance to the tyrosine kinase inhibitor STI 571 [abstract].","volume":"96","author":"Roumiantsev","year":"2000","journal-title":"Blood."},{"key":"2020021300141381000_B17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.293.5538.2163a","article-title":"Roots of clinical resistance to STI-571 cancer therapy [letter].","volume":"293","author":"Barthe","year":"2001","journal-title":"Science."},{"key":"2020021300141381000_B18","first-page":"2163","article-title":"Roots of clinical resistance to STI-571 cancer therapy.","volume":"293","author":"Hochhaus","year":"2001","journal-title":"Science [letter]."},{"key":"2020021300141381000_B19","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1126\/science.1062538","article-title":"Roots of clinical resistance to STI-571 cancer therapy [response].","volume":"293","author":"Gorre","year":"2001","journal-title":"Science."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/9\/3472\/1682653\/h80902003472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/9\/3472\/1682653\/h80902003472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T05:14:24Z","timestamp":1581570864000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/9\/3472\/53597\/High-frequency-of-point-mutations-clustered-within"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.9.3472","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}